Platforms
Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-05Jul 15, 2025
Cell-Line
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics
Selexis SA
PR-M03-18-NI-045Mar 13, 2018
License Agreement
Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates
Selexis SA
PR-M03-18-NI-009Mar 02, 2018